Literature DB >> 8841838

The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells.

J Van Wauwe1, F Aerts, H Van Genechten, H Blockx, W Deleersnijder, H Walter.   

Abstract

Pentamidine is an antiprotozoal drug with additional antiinflammatory activities that are not well understood. We now report that pentamidine inhibited the human whole blood production of the chemotactic cytokines (chemokines) interleukin (IL)-8, growth related gene alpha (GRO alpha) and monocyte chemotactic protein-1 (MCP-1). The title compound dose-dependently suppressed the lipopolysaccharide (LPS)- and phytohemagglutinin (PHA)-stimulated whole blood generation of these chemokines with IC50-values of 2.1 and 2.2 microM (IL-8), 2.4 and 1.8 microM (GRO alpha) and 2.8 and 2.4 microM (MCP-1). The inhibition was specific: when tested at 10 microM, pentamidine had no significant inhibitory effect on the PHA-induced generation of the non-chemotactic cytokines tumor necrosis factor-alpha (TNF-alpha), IL-1 beta, IL-2, IL-4, IL-5, IL-10 and interferon-gamma (IFN-gamma), except for a partial inhibition on IL-6. Time course experiments indicated that pentamidine (10 microM) retained its ability to inhibit PHA-stimulated IL-8 production even when its addition was delayed for up to 24h after mitogen stimulation. Furthermore, reverse transcription PCR studies showed that pentamidine had no effect on IL-8 mRNA expression. These findings indicate that pentamidine is a post-transcription acting inhibitor of human chemokine production. This activity may contribute to the anti-inflammatory action ascribed to the title compound.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841838     DOI: 10.1007/bf02252949

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  46 in total

1.  Effect of CC chemokines on mediator release from human skin mast cells and basophils.

Authors:  K Hartmann; F Beiglböck; B M Czarnetzki; T Zuberbier
Journal:  Int Arch Allergy Immunol       Date:  1995-11       Impact factor: 2.749

Review 2.  New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.

Authors:  S F Queener
Journal:  J Med Chem       Date:  1995-11-24       Impact factor: 7.446

Review 3.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

4.  Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells.

Authors:  F M Brennan; C O Zachariae; D Chantry; C G Larsen; M Turner; R N Maini; K Matsushima; M Feldmann
Journal:  Eur J Immunol       Date:  1990-09       Impact factor: 5.532

5.  Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo.

Authors:  D T Nguyen; M K Eskandai; L E DeForge; C L Raiford; R M Strieter; S L Kunkel; D G Remick
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

6.  Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.

Authors:  T Kambayashi; C O Jacob; D Zhou; N Mazurek; M Fong; G Strassmann
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

7.  Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups.

Authors:  S C Donnelly; R M Strieter; S L Kunkel; A Walz; C R Robertson; D C Carter; I S Grant; A J Pollok; C Haslett
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

8.  Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis.

Authors:  M Seitz; B Dewald; N Gerber; M Baggiolini
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Ligation of CD28 on resting T cells by its ligand B7 results in the induction of both Th1- and Th2-type cytokines.

Authors:  H Walter; S Schepensn; J Van Wauwe; M de Boer
Journal:  Eur Cytokine Netw       Date:  1994 Jan-Feb       Impact factor: 2.737

10.  Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.

Authors:  K Matsushima; C G Larsen; G C DuBois; J J Oppenheim
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  1 in total

1.  S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease.

Authors:  Carla Cirillo; Elena Capoccia; Teresa Iuvone; Rosario Cuomo; Giovanni Sarnelli; Luca Steardo; Giuseppe Esposito
Journal:  Biomed Res Int       Date:  2015-07-29       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.